Drug development programs for identification of new antineoplastic
agents involve extensive preclinical evaluation of vast
numbers of chemicals for detection of anti-neoplastic activity. Cell
culture systems have figured largely in the field of cancer
chemotherapy, where the potential value of such systems for
cytotoxicity and viability testing is now widely accepted.
The aim of this study is to evaluate cytotoxicity and viability
testing of new anti-neoplastic active ingredient compared to
Methotrexate and Adriamycin anti-neoplastic active ingredients
which are commonly used for cancer chemotherapy on HEPG2,
HEP2 and VERO cell lines.
Cytotoxicity, LD50, therapeutic dose, drug exposure, recovery
period and stability bioassay are determined.
Cytotoxicity bioassay of tested active ingredient on HEPG2 cells
showed punching of all monolayer cells with few regenerative cells
after 48 hr and no regenerative cells after 72 hr while Methotrexate
and Adriamycin showed 75% cytopathic effect on monolayer cells
after 24 hr then cells begins to regenerate with few rate after 48-72
hr.
Cytotoxicity bioassay of tested active ingredient on HEP2 cells
showed 25% cytopathic effect on monolayer cells then regenerated
to reach complete monolayer after 72 hr compared to
Methotrexate50% and Adriamycin 75% cytopathic effect on
monolayer cells then reached to 75% of monolayer after 72 hr.
Cytotoxicity of tested active ingredient onVero cells showed
retraction of monolayer cells then retains its original pattern after
24 hr of exposure while Methotrexate and Adriamycin showed
destruction of more 50% of monolayer cell population then reached
to 75% of monolayer after 72 hr.
In conclusion; cytopathological studies showed that the tested
active ingredient has low cytotoxicity, more stable and more
telorated compared to controls.